September 24, 2008
Visualization of Hypoxia-Inducible Factor-1 Transcriptional Activation in C6 Glioma Using Luciferase and Sodium Iodide Symporter Genes
By Yeom, Chan Joo Chung, June-Key; Kang, Joo Hyun; Jeon, Yong Hyun; Kim, Kwang Il; Jin, Yong Nan; Lee, You Mie; Jeong, Jae Min; Lee, Dong Soo
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor of hypoxic response in cancer cells and is associated with tumor progression, angiogenesis, metastasis, and resistance to therapy. We assessed whether the human sodium iodide symporter (NIS) reporter systems can be used to visualize transcriptional activation of HIF- 1 in C6 glioma. Methods: Two types of plasmid-expressing human NIS or luciferase (Luc) genes, controlled by 5 copies of hypoxia response element (5HRE), were constructed: p5HRE-NIS or p5HRE-Luc. C6 glioma cells were stably transfected with p5HRE-NIS or p5HRE-Luc plasmids (C6-5HRE-NIS or C6-5HRE-Luc). Hypoxic conditions were modeled by exposing culture medium to desferrioxamine (DFO) or a low oxygen atmosphere (
Solid tumors usually contain hypoxic tissues due to a combination of uncontrolled cell proliferation and insufficient and abnormal vascularization. Cancer cells express many genes to survive in anaerobic environments, and hypoxia-inducible transcription factor- 1 (HIF-1) is a key mediator. HIF-1 regulates the expressions of many hypoxia-inducible genes and thus facilitates adaptive response. HIF- 1 is a heterodimer composed of an HIF-1alpha, whose expression is dependent on cellular oxygen level, and a constitutively expressed HIF-1beta (aryl hydrocarbon receptor nuclear translocator) (1-3).
HIF-1alpha reacts quite differently at different cellular oxygen levels. Under normoxic conditions, the von Hippel-Lindau protein recognizes posttranslauonal modifications caused by iron or the oxygen-dependent hydroxylation of HIF-1alpha and induces the ubiquitin proteasomal degradation pathway; thus, it blocks the transcription of target genes. On the other hand, under hypoxic conditions, HIF-1alpha is activated through a multistep process involving its stabilization, nuclear translocation, and heterodimerization with the HIF-1beta subunit. In addition, HIF- 1alphabeta binds to a as-acting hypoxia response element (HRE) of the consensus sequence in the upstream site of more than 60 genes, which are also involved in cell proliferation and survival, tumor therapy resistance, glucose metabolism (e.g., glucose transporter 1), angiogenesis (e.g., vascular endothelial growth factor [VEGF]), metastasis, and apoptosis (2,4-7).
HIF-1alpha can also be upregulated via other mechanisms. For example, the inactivation of the von Hippel-Lindau tumor suppressor gene increases HIF-1alpha stabilization (8), and HIF1alpha protein synthesis can be induced in an oxygen-independent manner, such as by the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways, which are stimulated by growth factors, cytokines, and other signaling molecules (4). Cobalt chloride or iron chelators such as desferrioxamine (DFO) also stabilize HIF-1alpha by blocking HIF-1alpha posttranslational modification by prolyl hydroxylase (9,10).
Several methods have been developed to measure hypoxia or HIF-1 activation in solid tumors. Commonly used invasive methods include microelectrode oxygen concentration measurements (11), immunohistochemical stainings forpimonidazole (an exogenous hypoxic marker) (12,13), carbonic anhydrase IX (14), and HIF-Ialpha (75). In noninvasive methods, molecular imaging based on nuclear medicine and optical imaging systems offers another approach. Some investigators have tried to visualize tumor hypoxia by imaging l8F- fluoroerythronitroimidazole or ^sup 18^F-fluoromisonidazole (FMISO) using PET techniques (16). Recently, a cispromoter reporter gene imaging system was used to visualize hypoxia. ^sup 124^I-2'-fluoro- 2'-deoxy-1beta-D-arabinofuranosyl-5-iodouracil accumulates in hypoxic cells that express exogenously the HIF-1alpha-driven herpes simplex virus type 1 thymidine kinase gene (16). In addition, luciferase (13) and green fluorescence protein (17) have been used for optical imaging.
The sodium iodide symporter (NIS) gene is an imaging reporter gene used in nuclear medicine. NIS is an integral membrane protein and cotransports 2 sodium ions and 1 iodide ion into cells in normal thyroid tissue and in some nonthyroid tissues, such as salivary glands, stomach, thymus, and breast. As compared with conventional PET reporter genes, NIS has several advantages because it has a wide availability of substrates, such as the radioiodine ^sup 99m^Tc- pertechnetate. Moreover, these substrates are unlikely to influence the underlying cell biochemistry and accordingly are not metabolized in most tissues (18). Our groups and others have described the usefulness of NIS in the visualization of molecular-genomic phenomena, including gene expression, nuclear receptor activation, and target cell trafficking (19,20).
The purpose of the present study was to develop an NIS gene system to noninvasively image HIF-I transcriptional activation in C6 rat glioma. Firefly luciferase (Luc) and human sodium iodide symporter (hNIS) reporter genes were used for bioluminescence and scintigraphic imaging, and HIF-!-specific reporter systems were engineered using the hNIS and Luc genes. These systems were used to compare patterns of reporter gene expression with those of conventional hypoxic markers.
MATERIALS AND METHODS
DNA fragments encoding hNIS (kindly provided by Dr. Sissy Jhiang of Ohio State University) were inserted between BamH I and Xho I sites of the pcDNA3 vector (Invitrogen) to construct the plasmid pCMV-NIS. Luciferase was cloned from the pGL2 vector (Promega) and inserted between Sal I and Not I sites of the pIRES vector (Clontech) to construct the plasmid pCMV-Luc. The cytomegalovirus (CMV) promoter located between Nru I and Hind IH sites was removed from pCMV-NIS. The cDNA fragment bearing 5 repeats of HRE (HRE; CCACAGTGCATACGTGGGCTCCAA-CAGGTCCTCTT) from hVEGF and minimal SV40 promoter (5HRE) were prepared from the pGL2-5HRE-Luc plasmid (kindly provided by Dr. You Mie Lee (21)) by polymerase chain reaction (PCR) using the following primers: 5'-CCTAACTAGTCGTTC-CCACAGTGCATAC-3' (forward primer) and 5'-CCTAGCTAG-CCAGTACCGGAATGCCAAG-3' (reverse primer). PCR products were released by Nru I and Hind III and inserted into pCMV-NIS (described above) to construct the p5HRE-NIS plasmid (Fig. 1A).
To construct p5HRE-Luc (Fig. 1B), 5HRE fragments were prepared by PCR using the following primers: 5'-CCTATTCATATGCGTT-CCCACAGTGCATAC- 3' (forward primer) and 5'-CCTATTGCTAGCCAGTACCGGAATGCCAAG-3' (reverse primer). The CMV promoter of pCMV-Luc was replaced with the PCR products of 5HRE released by Nde I and Nhe 1.
Cell Culture and Hypoxia
C6 rat glioma cells (CCL-107; American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (Gibco) containing 1% antibiotic-antimycotic solution (10,000 IU of penicillin, 10,000 [mu]g of streptomycin per milliliter, 25 [mu] of amphotericin B per milliliter [Cellgro], and 10% [v/v] fetal bovine serum [Invitrogen]). Cells were cultured under normoxic conditions (5% CO2, 20% O2, and 75% N^sub 2^) in a humidified chamber at 37[degrees]C or under hypoxic conditions (
Establishment of Stable Cell Lines
C6 glioma cells were transfected with p5HRE-NIS (or pSHRE-Luc) using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's instructions. Cells were cultured in medium supplemented with 400-850 [mu]g of geneticin per milliliter (Invitrogen) to select stable transfectants for 2 wk. Established clonal lines were screened using ^sup 125^I uptake assay and bioluminescence assays, and after hypoxia had been induced in a hypoxic chamber (
In Vitro ^sup 125^I Uptake Assay
To assess hypoxia-inducible HNIS activity, ^sup 125^I uptake levels were determined using a modification of the method described by Weissetal. (22).C6-5HRE-NIS reporter cells were seeded at 1 ? 105 cells per well in 24-well plates in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After 24 h, cells were treated with DFO at 100,200, or 400 [mu]M (Sigma Chemical Co.) or exposed to hypoxia (
In Vitro Bioluminescence Assays
Bioluminescence assays were performed using a luciferase assay kit (Tropix). Cells were plated and treated with DFO or incubated in a hypoxic chamber, as described previously. After induction of hypoxic conditions, cells were washed twice with 1 mL of Ix PBS, and lysis solution was then added to each well. Cell lysates were transferred to a microplate, and bioluminescences were measured using a Wallac 1420 VICTORS V (PerkinElmer Life and Analytic Sciences). Bioluminescent signals were normalized versus the percentage of viable cells present as determined by trypan blue exclusion assays.
Reverse-Transcription PCR (RT-PCR) Analysis of Transcripts from hNIS, Luc, and VEGF Genes Specifically Targeted by HIF-1
C6 parental cells and C6-CMV-NIS (the expression of the hNIS gene is controlled by CMV independently of hypoxia) or C6-CMV-Luc (the expression of the Luc gene is controlled by CMV independently of hypoxia) cells and C6-5HRE-NIS or C6-5HRE-Luc reporter cells were incubated under normoxic or hypoxic (
5'-CTACGAGTACCTGGAGATGC-3' (NIS forward),
5'-GTCGCAGTCAGTGTAGAACA-3' (NIS reverse),
5'-ATGGAAGACGCCAAAAACATAA-3' (Luc forward),
5'-TTACAATTTGGACTTTCCGCC-3' (Luc reverse),
5'-GTCACATCTGCAAGTACGTTCG-3' (VEGF reverse),
5'-TGACGGGGTCACCCAACTGTGCCCATCTA-3'' (beta-actin forward), and
5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3' (3'-actin reverse).
PCR was performed using an initial denaturation at 95[degrees]C for 10 min, 25 amplification cycles (30 s at 94[degrees]C, 30 s at 55[degrees]C, and l min at 72[degrees]C), and a final extension at 73[degrees]C for 7 min. All PCR products were analyzed by ethidium bromide-stained agarose gel electrophoresis.
C6 and C6-CMV-NIS (or C6-CMV-Luc) and C6-5HRE-NIS (or C6-5HRE- Luc) reporter cells were incubated in a normoxic or hypoxic chamber (
After the proteins were transferred to nitrocellulose membranes (Schleicher & Schuell) by electroblotting, membranes were blocked with 5% skim milk in Tris-buffered saline (20 mM Tris, 137 mM sodium chloride, and 0.1 % polysorbate 20) at room temperature for 1 h. The membranes were then incubated with monoclonal mouse antihuman/mouse/ rat HTF-1alpha antibodies (1:1,000 dilution, Clone 241809; R&D Systems) and monoclonal mouse antihuman NIS (1:2,000 dilution, Clone FP5A; LAB VISION) (23) or monoclonal mouse anti-luciferase (1:1,000 dilution, Clone Luc-1 ; Sigma) (24) and alpha-tubulin as an internal loading control ( 1:2,500 dilution. Clone B-5-1 -2; Sigma) for 1 h. After the membranes were washed 3 times with Tris-buffered saline, they were incubated with secondary antimouse horseradish peroxidase- conjugated antibody (1:2,000 dilution) for 1.5 h. Immunoreactive bands were visualized using enhanced chemiluminescence reagents (Roche) and LAS-3000 (Fuji Film).
Generation of Tumor Xenografts in Nude Mice
All procedures involving animals were approved by the Institutional Animal Care and Use Committee at Seoul National University and were consistent with the Guide for the Care and Use of Laboratory Animals (25).
Three groups of adult male BALB/c nu/nu mice weighing 20 g on average were used to develop in vivo models of tumor tissue hypoxia. The first group (n = 5) was used to visualize DFO-induced HIF-1 transcriptional activity in tumor xenografts using a scintigraphic imaging system (NIS group 1). The second group (n = 4) was used to visualize HIF-1 transcriptional activity in natural hypoxic region by growing tumors using a scintigraphic imaging system (NIS group 2). In NIS group 3, different cell lines were implanted as follows: 1 x 10^sup 6^ C6 cells in the right shoulder, 1 x 10^sup 6^ C6- CMV-NIS cells in the left thigh, and 1 x 10^sup 6^ C6-5HRE-NIS cells in the right thigh (NIS group). Other animals (n = 5) were used to visualize HIF-1 transcriptional activity using a bioluminescence imaging system; 3 different cell lines were injected subcutaneously as follows: 1 x 10^sup 6^ C6 cells in the right shoulder, 1 x 10^sup 6^Co-CMV-Luc cells in the left thigh, and 1 ? 106 C6-5HRE-Luc cells in the right thigh (Luc group).
Tumor xenografts (
In Vivo Scintigraphic and Bioluminescent Imaging
In the NIS group, 30 min after an introperitoneal injection of 11.1 MBq (300 [mu]Ci) of ^sup 99m^Tc-pertechnetate per mouse, the mice were placed in a spread-prone position and scanned with a gamma- camera (ON 410; Ohio Nuclear) equipped with a 6-mm-sized pinhole collimator.
In the Luc group, mice were injected intraperitoneally with an aqueous solution of the Luc substrate luciferin (5 mg/mouse; Molecular Probes) 10 min before bioluminescence imaging. Mice were anesthetized with isofturane and transferred into a light-tight chamber equipped with a charge-coupled device camera (IVIS200; Xenogen Corp.) running Live Image software (Xenogen Corp.) to obtain bioluminescent images.
In NIS group 1 and the Luc group, to enhance the transcriptional activation of HIF-I transiently, hypoxia-mimicking DFO was injected intraperitoneally at 300 mg/kg (20,27). Mice were imaged using a gamma-camera (or a charge-coupled device camera) 4,24, and 48 h after DFO administration. In NIS group 2, xenografts were grown up to 2 cm in diameter (for 3 wk) to develop a natural hypoxic region. Scintigraphic images were acquired sequentially during tumor growth.
Biodistribution, Autoradiography, and Immunohistochemistry (IHC)
IHC and autoradiography were performed after tumors had been grown for 3 wk to compare reporter protein expression with hypoxic regions.
In NIS group 2 (n = 4), biodistribution studies, phosphor plate digital autoradiography, and IHC study were performed to compare the intratumoral distributions of ^sup 99m^Tc-pertechnetate and pimonidazole (a chemical adduct that detects tissue hypoxia). Ninety minutes before sacrifice, each mouse in NIS group 2 was administered a 0.1-mL injection (60 mg/kg of body weight intraperitoneally) of pimonidazole hydrochloride (Hypoxyprobe-1 Plus Kit; Chemicon International), according to the manufacturer's instructions (12). Thirty minutes before sacrifice, ^sup 99m^Tc-pertechnetate (about 37 MBq in 0.1 mL) was injected intraperitoneally into each mouse. After sacrifice, the entire tumors were removed, weighed, and measured for radioactivity, and percentages of injected dose per gram (%ID/g) of tumor were calculated. Tumors were then snapfrozen, sectioned into 20-[mu]m (for autoradiography) or 4-[mu]m (for hematoxylin and eosin and IHC) slices, and immunostained with fluorescein isothiocyanate (FTTC)-conjugated primary antibody against pimonidazole (1:50) and horseradish peroxidase-labeled secondary anti-FITC monoclonal antibody (1:50) supplied with the kit used (Hypoxyprobe-1 Plus Kit), according to a modification of the manufacturer's instructions as described previously (12). In the Luc group, mice were sacrificed 90 nun after being injected with pimonidazole hydrochloride. Serial sections of C6-5HRE-Luc tumor paraffin blocks were cut at 4 [mu]m, freed of paraffin in HistoClear (National Diagnostics), and rehydrated through decreasing concentrations of ethanol (100% and 95%). After autoclave treatment (3 min at 121[degrees]C), endogenous peroxidase activity was quenched with 3% H^sub 2^O^sub 2^ in methanol for 5 min at room temperature. This was followed by rinsing in Tris-buffered saline for 2 min at room temperature. To obtain pimonidazole staining, sections were first incubated with an FITC- conjugated primary antibody against pimonidazole (1:50 dilution; Hypoxyprobe-1 Plus Kit) for l h at room temperature, then with a horseradish peroxidase-labeled secondary anti-FTTC monoclonal antibody (1:50 dilution; Hypoxyprobe-1 Plus Kit) for 30 min at room temperature, as described previously (12). To obtain luciferase staining, sections were first incubated with a goat antifirefly luciferase polyclonal antibody (1:50 dilution; Abeam Ltd.) for l h at room temperature, then with a biotin-coupled antigoat secondary antibody (1:500 dilution; DAKO) for 30 min at room temperature. Finally, sections were incubated with streptavidin conjugated with horseradish peroxidase ( 1:400 dilution; DAKO). To reveal the peroxidase activity, 3,3'-diaminobenzidine was used as chromogenes. Then samples were slightly counterstained with hematoxylin.
Quantitation of in vivo scintigraphic and bioluminescent images was performed by using an image-analysis program (Multi Gauge, version 2.02; Fuji Film). Regions of interest (ROIs) were drawn on each scintigraphic and bioluminescent image to quantify radionuclide uptake or the optical flux (photons/s) of the target signal. The same size of ROI was selected for comparison. Statistical significances of all in vitro and biodistribution results were determined using a 2-sidedStudent t test with equal variances. The ROI results for NIS group 2 and the LHC group in vivo imaging were determined using a paired t test. A value of P less than 0.05 was considered significant. All statistical analysis was performed using Excel 2003 (Microsoft).
Establishment of Hypoxia-Sensitive HIF-1-Specific Reporter Gene Systems
Time- and concentration-dependent increases in radioactivity (or bioluminescence signals) were achieved in C6-5HRE-NIS (or C6-5HRE- Luc) stable cells under hypoxia. A 3-fold increase of radioactivity in C6-5HRE-NIS cells was observed after 24 h of hypoxic chamber incubation (
FIGURE 2. In vitro effect of hypoxia on activities of reporter proteins according to radioiodide uptake and luciferase assay. C6- 5HRE-NIS orC6-5HRE-Luc cells were seeded in 24-well plates and exposed to normoxia or low atmospheric oxygen (
RT-PCR analysis (Fig. 3A) showed marked VEGF and hNIS (or Luc) induction controlled by 5HRE in C6-5HRE-NIS or C6-5HRE-Luc cells after 24 h of incubation in a hypoxic chamber. But no change was observed in C6-CMV-NIS or C6-CMV-Luc cells under normoxic and hypoxic conditions, and no expression of hNIS (or Luc) was observed in C6 cells.
Western blot analysis (Fig. 3B) showed that the expressions of stable HIF-Ia proteins, translocated to the nucleus, increased strongly in reporter cells incubated for 24 h in a hypoxic chamber versus reporter cells under normoxic conditions. In addition, hNIS or Luc expression increased in reporter cells after 24 h of hypoxic chamber incubation, but no change was observed in the expression of a-tubulin, which was used as an internal control. We also observed hNIS (or Luc) mRNA and protein level even under normoxic conditions, suggesting 5HRE promoter leakiness for both reporter gene systems.
FIGURE 3. Induction of HIF-1alpha and HIF1 target genes. (A) RT- PCR analysis of transcripts from HIF-1 target genes, VEGF, and hNIS or Luc reporter genes in normoxic (N) or hypoxic (H) C6 and C6CMV- NIS or C6-CMV-LUC and C6-5HRENIS or C6-5HRE-LUC reporter cells. Cells were incubated under N or H (
Reporter Gene Imaging That Visualized Transcription-Activated HIF- 1
In the Luc group, the bioluminescent signal of C6-5HRE-Luc tumors, versus DFO-pretreated images, time-dependently increased. The bioluminescent signal was not significantly elevated in C6 or C6- CMV-Luc tumors (Fig. 4A).
In NIS group 1, the tracer uptake of C6-5HRE-NIS tumors increased after DFO treatment, compared with at baseline (Fig. 5A), but this difference was not statistically significant. In naturally occurring hypoxic mouse models, NIS group 2, the radioactivities of growing hypoxic C6-5HRE-NIS tumors (2 cm in diameter) significantly increased versus the radioactivities of prehypoxic C6-5HRE-NIS tumors (1 cm in diameter). However, radioactivity decreased in C6- CMV-NIS tumors in the NIS group (Fig. 5B).
ROI analysis of bioluminescence images showed a 2- or 3-fold increase in signal at 4 or 24 h after DFO treatment in C6-5HRE-Luc xenografts versus pre-DFO tumors (P
Biodistribution and Comparison Between Autoradiography and IHC
In the biodistribution of ^sup 99m^Tc-pertechnetate in mice (n = 4) of NlS group 2, C6-5HRE-NIS tumors accumulated more radioactivity (24.82 +- 3.98 %ID/g) than did C6 (2.85 +- 0.59 %ID/g) or C6-CMV- NIS (12.3 +- 3.08 %ID/g) tumors (Fig. 5D) (P
In this study, 2 different reporter gene systems were developed, controlled by 5HRE, to evaluate HIF-1 transcriptional activity. In addition, in vitro tests, in vivo small-animal studies, and biodistribution, autoradiography, and IHC experiments were performed.
FIGURE 4. Bioluminescence imaging of HIF-1 transcriptional activation in tumors of Luc group. (A) Control image (no DFO treatment) was acquired 2 wk after tumor challenge (a = C6, b = C6- CMV-Luc, and c = C6-5HRE-Luc), and then images were sequentially obtained at 4 and 24 h after systemic injection of DFO. (B) ROIs were drawn on bioluminescence images to quantify photon fluxes per second. Statistical significances of ROI results were determined using paired t test. Time-dependent increases in bioluminescent signals were detected. *P
FIGURE 5. Scintigraphic imaging of HIF-1 transcriptional activation in NIS group tumors. (A) Scintigraphic imaging of NIS group 1. In NIS group 1, control scintigraphic image (no DFO treatment) was acquired 2 wk after tumor challenge (a = C6, b = C6- CMV-NIS, c = C6-5HRE-NIS, Thy = thyroid, St = stomach, BI = bladder), and post-DFO image was observed 24 h after administering DFO intraperitoneally. (B) Scintigraphic imaging of NIS group 2. In another hypoxiainduced NIS group 2, tumors were grown for 3 wk (diameter, 2 cm) to allow hypoxia to occur naturally. (C) ROIs on scintigraphic images of NIS group 2. ROIs of thyroid and tumor were drawn on scintigraphic images from B. Tumor or thyroid ratio was calculated for individual mice (n = 4). Statistical significances of ROI results were determined using paired t test. Scintigraphic signal in 3-wk C6-5HRE-NIS tumors was significantly higher than in 2- wk tumors, whereas no significant change was detected in C6 or C6- CMV-NIS tumors. *P
FIGURE 6. Comparison between ^sup 99m^Tc autoradiography and pimonidazole staining of tumors in NIS group 2 and immunohistochemical staining for pimonidazole and luciferase in Luc group. This autoradiograph of C6-5HRE-NIS tumor section (C) has higher ^sup 99m^Tc intensity than C6 (A) or C6-CMV-NIS (B) tumor sections. F shows square area in C at higher magnification, lmmunohistochemical staining ( x 40) pattern observed using antipimonidazole antibody (D) shows similar distribution of ^sup 99m^Tc in 3-wk-grown C6-5HRE-NIS tumor section (F). Colocalization immunohistochemical study ( x 40) for hypoxic marker, pimonidazole (E), and reporter protein, luciferase (G), was performed using 3-wk- grown C6-5HRE-Luc tumors in Luc group. Hypoxic areas as defined by pimonidazole-positive staining in E were similar to luciferase- positive areas in G. Nx = normoxic region; Hx = hypoxic region. Bars indicate 200 [mu]m.
In vivo scintigraphy and bioluminescence images showed elevated HIF-1 transcriptional activity after DFO treatment. In addition, in line with natural tumor growth, scintigraphy showed increased C6- 5HRE-NIS, compared with C6-CMV-NIS, tumor radioactivity. These results hold true in in vitro as well as in vivo studies (data not shown).
However, our reporter systems still have some limitations. At first, our reporter system showed a leaky reporter gene expression even under normoxic conditions. Harada et al. constructed a Luc gene fused with the oxygen-dependent degradation (ODD) domain, which is controlled under the 5HRE promoter (5HREp-ODD-Luc), to improve this problem of the promoter leakiness of a 5HRE promoter (30). Second, the CMV promoter, compared with the 5HRE construct, had a weak signal in vitro and in vivo. The reason might be that it takes a long time to establish C6-CM V-Luc or C6-CMV-NIS stable cells, which undergo more passages than C6-5HRE-LUC or C6-5HRE-NIS cells. We already reported that gene silencing based on methylation of CpG sites and histone deacetylation in CMV constructs might result in the decrease of transgene hNIS gene expression after several passages and could be reversed by DNA demetnylation and histone deacetylation inhibition (31). Third, the low sensitivity of NIS reporter genes explains the lack of a significant increase in DFO- induced scintigraphic images versus DFO-induced bioluminescent images (19,32). And the higher accumulations of ^sup 99m^Tc- pertechnetate observed in naturally occurring hypoxic tumors, compared with DFO-induced tumors in the NIS group, is probably explained by the different effects of long-term hypoxia for 1 wk and transient DFO treatment. There appeared to be a yet undefined threshold of HIF-1 activation below which p5HRE-NIS expression was not detected, and we did not confirm that the degree of HIF-1 activation is correlated with the degree of promoter activation.
Two different imaging systems, which have their own advantages and disadvantages, were used with the hNIS and Luc reporter genes. Although bioluminescence imaging is technically simple and highly sensitive with minimal background interference (19,32), it is of limited use in large-animal studies, especially in human applications, because of light absorption by tissue (33). On the other hand, the nuclear medicine imaging reporter gene NIS is applicable in large animals and humans. Moreover, although NIS has low sensitivity, compared with the luciferase system, it has advantages such as ready availability and no requirement for complicated radiochemistry of its substrates, such as radioiodine or ^sup 99m^Tc-pertechnetate, which can be used in place of iodide. In addition, the metabolic clearances of these substrates are well understood, and these substrates are known not to induce an immune response (18).
In this study, ex vivo immunohistochemical staining and autoradiography suggested that increased imaging signals, that is, radioactivities and bioluminescent intensities, in tumors were induced by increased imaging reporter gene expressions, which were stimulated under hypoxic condidons. Autoradiography and IHC of C6- 5HRE-NIS tumors demonstrated that the localization of accumulated radioactivity was similar to that of pimonidazole (the hypoxic region), which implies that the AMS reporter system controlled by 5HRE specifically undergoes transcriptional regulation via HIF-1 activation. The immunostaining study of C6-5HRE-Luc tumors showed concordance between luciferase and pimonidazole staining findings and thus demonstrated Luc gene expression in hypoxic tumor regions.
Visualization of hypoxic tumors is quite important in the management of cancer with chemotherapy or radiotherapy. Hypoxic tumors are usually resistant to chemotherapy or radiotherapy. In the visualization of tumor hypoxia, these reporter imaging systems differ in several aspects from conventional hypoxic PET images obtained using ^sup 18^F-fluoromisonidazole, ^sup 60^Cu-diacetyl- bis(N^sup 4^-methythiosemicarbazone), or others, which concern binding to macromolecules in hypoxic cells. In our system, exogenous gene transfection is needed, which presents difficulties in practice. However, hypoxic PET images can visualize hypoxic areas only and tissue hypoxia is only 1 stimulator of HIF-1 activation. Several other tumor factors, such as growth factors, cytokines, and reactive oxygen species induced by ionizing radiation (34,35), also stimulate HIF-1alpha activation. These factors control the transcriptions of several genes involved in cancer biology, for example, in angiogenesis, cell survival, glucose metabolism, and invasion (4). In addition, it has been suggested that not only hypoxia but also sensitivity of tumor vasculature to radiation is a major determinant of response to radiotherapy. Successful radiotherapy is dependent on the destruction of the tumor-feeding vasculature, as the survival of tumors is highly reliant on vessels. Activation of HIF-1 itself leads to radioresistance by inducing the expression of VEGF, erythropoietin, transforming growth factor- beta3, plasminogen activator inhibitor-1, and transferrin genes, which are highly active in angiogenesis. Moreover, radiotherapy upregulates HIF-1 levels and activity of tumor cells because of reactive oxygen species by radiation-induced tumor reoxygenation (34). Therefore, the visualization and tumor therapy targeting for HIF-1 activation is more important than that for hypoxia itself when assessing cancer behavior. Reporter gene imaging might offer a novel means of investigating molecular-genomic events in cancer.
We developed HIF-1-specific bioluminescence and scintigraphic imaging systems in tumors. This is the first study, to our knowledge, to visualize HIF-1 transcriptional activation using hNIS, a nuclear medicine imaging reporter gene that is applicable in large animals and humans. These noninvasive imaging tools can be used to investigate HIF-1-associated molecular-genomic events and could be used to predict the effects of chemotherapy and radiotherapy in cancer.
This work was supported by grant 03-2007-006 from the Seoul National University Hospital research fund (2007).
1. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270:1230-1237.
2. Unruh A. Kessel A. Mohamed HG, et al. The hypoxia-inducible factor-1alpha is a negative factor for tumor therapy. Oncogene. 2003;22:3213-3220.
3. Lungu GF, Li ML, Xie X. Wang LV, StoicaG. In vivo imaging and characterization of hypoxia-induced neovascularization and tumor invasion. Int J Oncol. 2007; 30:45-54.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732. 5. Pouyssegur J, Dayan F, Mazure NM. Hypoxie signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437-443.
6. Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible- faclor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 2006;7:41-45.
7. Ivan M. Kondo K, Yang H, et al. HIFalpha targeted for VHL- mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468.
8. Maxwell PH, Wiesener MS, Chang GW. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen- dependent proteolysts. Nature. 1999;399:271-275.
9. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia- inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-578.
10. Semenza GL. Perspectives on oxygen sensing. Cell. 1999;98:281- 284.
11. Cardenas-Navia LI, Yu D, Braun RD. Brizel DM. Secomb TW, Dewhirst MW. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 2004;64:6010-6017.
12. Samoszuk MK, Walter J, Mechetner E. Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. J Histochem Cytochem. 2004;52:837-839.
13. Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2- methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006;66:11991-11997.
14. Kaluz S, Kaluzova M, Stanbridge EJ. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SPI activity: identification of a novel type of hypoxia-responsive enhancer. Cancer Res. 2003;63:917-922.
15. Blanco Pampin J, Garcia Rivera SA, Otero Cepeda XL, Vazquez Boquete A, Forteza Vila J, Hinojal Fonseca R. Immunohistochemical expression of HIF-1alpha in response to early myocardial ischemia. J Forensic Sci. 2006;51:120-124.
16. Wen B, Burgman P, Zanzonico P, et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression: comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging. 2004;31:1530-1538.
17. Liu J. Qu R. Ogura M, Shibata T, Harada H, Hiraoka M. Real- time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo). 2005;46:93-102.
18. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188-1200.
19. Shin JH. Chung JK, Kang JH. el al. Noninvasive imaging for monitoring of viable cancer cells using a dual-imaging reporter gene. J Nucl Med. 2004; 45:2109-2115.
20. Kim KI, Chung JK, Kang JH. et al. Visualization of endogenous p53-mediated transcription in vivo using sodium iodide symporter. Clin Cancer Res. 2005;11:123-128.
21. Jeong CH, Lee YM, Choi KS, et al. Hypoxia-responsive element- mediated soluble Tie2 vector exhibits an anti-angiogenic activity in vitro under hypoxic condition. Int J Oncot. 2005;26:211-216.
22. Weiss SJ, Phil p NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat lhyroid, Endocrinology. 1984;114:1090-1098.
23. Castro MR, Bergert ER. Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab. 1999;84:2957- 2962.
24. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol. 1987;7:725-737.
25. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 19%.
26. Prass K, Ruscher K, Karsch M. et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blottd Flow Metab. 2002;22:520-525.
27. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, Sharp FR. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol. 2000;48:285-296.
28. Huang LE. Arany Z. Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox- sensitive stabilization of its alpha subunil. J Biol Chem. 1996;271:32253-32259.
29. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Amt transcription factor. Proc Natl Acad Sci USA. 1997;94:5667-5672.
30. Harada H, Kizaka-Kondoh S, Itasaka S, et al. The combination of hypoxiaresponse enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun. 2007;360:791-796.
31. Kim YH. Lee DS, Kang JH. et al. Reversing the silencing of reporter sodium/ iodide symporter transgene for stem cell tracking. J Nucl Med. 2005;46:305-311.
32. So MK, Kang JH. Chung JK. et al. In vivo imaging of retinoic acid receptor activity using a sodium/iodide symporter and luciferase dual imaging reporter gene. Mol Imaging. 2004;3:163-171.
33. Min JJ, Gambhir SS. Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects. Gene Ther. 2004;11:115-125.
34. Moeller BJ. Cao Y, Li CY, Dewhirst MW. Radiation activates HTF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429-441.
35. Semenza GL. Intralumoral hypoxia, radiation resistance, and HIF-1 Cancer Cell. 2004;5:405-406.
Chan Joo Yeom1,2, June-Key Chung1,2, Joo Hyun Kang3, Yong Hyun Jeon1,2, Kwang II Kim1,2, Yong Nan Jin1,
You Mie Lee4, Jae Min Jeong1,2, and Dong Soo Lee1,2
1 Department of Nuclear Medicine, Tumor Immunity Medical Research Center, Laboratory of Molecular imaging and Therapy of Cancer
Research Institute, Seoul National University College of Medicine, Seoul, Korea; 2 Institute of Radiation Medicine, Medical Research
Center, Seoul National University, Seoul, Korea; 3 Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Science,
Seoul, Korea; and 4 Kyungpook National University College of Nature Sciences, Daegu, Korea
Received Jun. 21, 2007; revision accepted May 20, 2008.
For correspondence or reprints contact: June-Key Chung, Department of Nuclear Medicine, Seoul National University College of Medicine, 23 Yongondong, Chongno-gu, Seoul, 110-744, Korea.
E-mail: [email protected]
COPYRIGHT (c) 2008 by the Society of Nuclear Medicine, Inc.
Copyright Society of Nuclear Medicine Sep 2008
(c) 2008 Journal of Nuclear Medicine, The. Provided by ProQuest LLC. All rights Reserved.